Psoriatic Disease
Q&A: Expert dives into first-ever national report detailing health impacts of psoriasis
Earlier this year, the National Psoriasis Foundation published an extensive report on the health impacts of psoriasis, including data on social stigma associated with the disease, health disparities and comorbidities.
Patients ‘very skilled’ at monitoring own non-musculoskeletal psoriatic arthritis features
WASHINGTON — Dactylitis, psoriasis and other non-musculoskeletal manifestations of psoriatic arthritis can be accurately monitored through patient self-reporting, according to data presented at ACR Convergence 2024.
Deucravacitinib superior to placebo for achieving psoriatic arthritis MDA at 16 weeks
Deucravacitinib is superior to placebo for improving response across all domains of minimal disease activity criteria in patients with psoriatic arthritis at 16 weeks, according to data published in Rheumatology.
VIDEO: Diagnostic challenges in psoriatic arthritis
Ethan Craig, MD, spoke with Healio about diagnostic challenges in psoriatic arthritis.
FDA approves higher-dose Bimzelx prefilled syringes, autoinjectors
The FDA has approved 320 mg pre-filled syringes and autoinjectors of Bimzelx for the treatment of active psoriatic arthritis with coexisting moderate-to-severe plaque psoriasis, according to a press release from UCB.
Apremilast improves pain, disease activity in early oligoarticular psoriatic arthritis
Treatment with apremilast led to improved clinical and patient-reported outcomes in early oligoarticular psoriatic arthritis at 16 weeks, according to data published in Annals of the Rheumatic Diseases.
Dual therapy can have ‘synergistic effect’ in difficult-to-treat inflammatory diseases
SAN DIEGO — Certain dual therapy strategies, including interleukin-17 plus IL-23 inhibition, or Janus kinase inhibitors alongside TNF inhibitors, can be effective for difficult-to-treat inflammatory diseases, according to a speaker here.
‘It’s going to be ubiquitous’: Weight loss drugs may aid rheumatic disease treatment
SAN DIEGO — GLP-1 agonists and other drugs that have recently made headlines for their weight loss applications will be useful in helping patients meet goals in psoriatic arthritis and other rheumatic diseases, according to a speaker here.
VIDEO: Psoriasis fundraising event is ‘a great way ... to give back to our patients’
PHILADELPHIA — Members of the psoriatic disease community recently gathered at the Philadelphia Zoo to raise funds that will be used to support patients through research and advocacy.
Psoriatic arthritis activity measured via DAPSA28 ‘highly analogous’ to DAPSA gold standard
The 28-joint Disease Activity Index for Psoriatic Arthritis score is superior to the DAS28-CRP score as a measure of disease activity in PsA if the “gold standard” DAPSA 66/68 joint counts are not available, according to data.